Articles From: GAIN Capital to Acquire GFT; Announces Preliminary First Quarter Results to Galena Biopharma Reports Year-End 2012 Financial Results

- Transformative acquisition provides significant scale along with revenue and product diversification - Combined 2013 revenue run-rate of $329 million and pro forma EBITDA run-rate of $77 million based on Q1 2013 results - Pro forma client assets of approximately $650 million and funded accounts of 139,710 as of March 31, 2013 - Estimated first year operating synergies of $35-$45 million - Accretive in the first full quarter following closing BEDMINSTER, N.J. , April 25, 2013 /PRNewswire/ --  GAIN Capital Preliminary First Quarter 2013 Results: Revenues increased 50% year-over year, to $49.8 million EBITDA of $7.5 million , up from $1.3 million ; 15% EBITDA margin Net income of $4.3 million , or $0.11 per diluted share Client assets reached $456.9 million ; Funded accounts increased 36% to 100,020 GAIN Capital Holdings, Inc. (NYSE: GCAP, "the Company") today announced that it has signed a definitive

-Plan provides Board opportunity to carefully evaluate FXCM proposal and consider alternatives to maximize shareholder value- BEDMINSTER, N.J. , April 9, 2013 /PRNewswire/ -- GAIN Capital Holdings, Inc. (NYSE: GCAP, "the Company") announced today that its Board of Directors has adopted a stockholder rights plan.

BEDMINSTER, N.J. , April 9, 2013 /PRNewswire/ -- The Board of Directors of GAIN Capital Holdings, Inc. (NYSE: GCAP) , a global provider of online trading services, announced that it received FXCM Inc.'s letter dated April 8, 2013 , which contains a proposal to acquire GAIN for 0.3996 shares of FXCM Class A common stock for each share of GAIN common stock.

BEDMINSTER, N.J. , April 25, 2013 /PRNewswire/ -- The Board of Directors of GAIN Capital Holdings, Inc. (NYSE: GCAP) , a global provider of online trading services, today announced that it has rejected an unsolicited written proposal from FXCM Inc. to acquire GAIN for 0.3996 shares of FXCM Class A common stock for each share of GAIN common stock.

--Gain rejects $210 million offer from FXCM --Gain plans to buy GFT for $107.8 million , instead --GFT purchase "not a reaction" to FXCM offer --Gain signed letter of intent to buy GFT in December By Nicole Hong and Jacob Bunge Currency brokerage Gain Capital Holdings LLC (GCAP) on Thursday rejected a takeover offer from larger rival FXCM Inc. (FXCM) and instead disclosed a deal to acquire Global Futures & Forex Ltd.

NEW YORK, Feb.

NEW YORK, April 19, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased the common stock of Avid Technology, Inc. ("Avid" or the "Company") (Nasdaq:AVID) between April 22, 2011 to February 22, 2013, seeking remedies under the federal securities laws.

NEW YORK, May 8, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Northern District of Texas on behalf of all persons or entities who purchased the common stock of Digital Generation, Inc. ("Digital") (Nasdaq:DGIT) between June 20, 2011 and February 19, 2013, seeking remedies under the federal securities laws.

NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Northern District of Illinois on behalf of all persons or entities who purchased the common stock of Great Lakes Dredge & Dock Corporation ("Great Lakes" or the "Company") (Nasdaq:GLDD) between August 7, 2012 and March 14, 2013, seeking remedies under the federal securities laws.

NEW YORK, March 29, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Southern District of Texas on behalf of purchasers of Harvest Natural Resources Inc. ("Harvest" or the "Company") (NYSE:HNR) between May 7, 2010 and March 18, 2013, seeking remedies under the federal securities laws.

NEW YORK, March 22, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in United States District Court for the Southern District of California on behalf of purchasers of Maxwell Technologies, Inc. ("Maxwell" or the "Company") (Nasdaq:MXWL) securities between April 28, 2011 and March 7, 2013, inclusive (the "Class Period"), seeking remedies under the federal securities laws.

NEW YORK, March 22, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of purchasers of securities of Spectrum Pharmaceuticals, Inc. ("Spectrum" or the "Company") (Nasdaq:SPPI) between August 8, 2012 and March 12, 2013, inclusive (the "Class Period"), seeking remedies under the federal securities laws.

NEW YORK, April 22, 2013 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all persons or entities who purchased the common stock of UniTek Global Services, Inc. ("UniTek" or the "Company") (Nasdaq:UNTK) between May 18, 2011 through April 12, 2013, seeking remedies under the federal securities laws.

Gaining Altitude - Laurentian Bank Holds Its 2013 Annual Meeting Canada NewsWire MONTREAL , March 19, 2013 /CNW Telbec/ - During Laurentian Bank's Annual Meeting of Shareholders held today at the Montréal Science Centre, the organization's senior management presented an overview of results for the fiscal year ended October 31, 2012 .

LAS VEGAS, March 26, 2013 (GLOBE NEWSWIRE) -- Galaxy Gaming, Inc. ( GLXZ ), announced today it has received approval from the Maryland Lottery and Gaming Control Agency to provide its products to casinos in the state.

Highlights Reasons Galbraith Believes Whiting USA Trust I is Extremely Overvalued at Current Price NEW YORK , April 30, 2013 /PRNewswire/ -- Galbraith Global Investment Management, LP ("Galbraith"), issued a warning today to investors of Whiting USA Trust I ("the Trust" or "WHX") (NYSE:WHX) that Galbraith believes WHX's current unit price is divorced from what it believes is the inherent value of the Trust.

BASKING RIDGE, N.J. , March 21, 2013 /PRNewswire/ -- Galderma, a leading global pharmaceutical company focused on dermatology, wanted a cost-efficient means of increasing the capacity of its IT global network infrastructure to support its increasingly data-intensive workload.

- Galectin Therapeutics and Icahn School of Medicine at Mount Sinai Data Presented at the International Liver Congress 2013 - NORCROSS, Ga.

Galectin Therapeutics (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today the establishment of a collaborative drug discovery program with Dr.

James Czirr, Executive Chairman of Galectin Therapeutics (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, will be a guest on “The RedChip Money Report”™ television program featuring emerging growth companies on FOX Business News, Saturday, February 9, 2013 at 2:30 p.m. Eastern.

Galectin Therapeutics (NASDAQ: GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that it submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) on January 30, 2013.

NORCROSS, Ga.

NORCROSS, Ga.

-- Abstract Accepted for Presentation at the International Liver Congress 2013 --

Former Silicon Valley Leaders Say Atlanta Emerging as "Silicon Valley for Biotech" and Curing Big Diseases NORCROSS, Ga.

Abstral® was approved in the U.S. in 2011 and is the first and only fentanyl sublingual tablet for the management of breakthrough cancer pain in opioid tolerant patients.

Abstral ® (fentanyl) Sublingual Tablets are an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impacts the majority of cancer patients at some point in their care.

LAKE OSWEGO, Ore., March 14, 2013 (GLOBE NEWSWIRE) -- Galena Biopharma (Nasdaq:GALE) , a biopharmaceutical company developing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, announced that independent research firm, Frost & Sullivan, has recognized Galena Biopharma with the 2013 Global Frost & Sullivan Award for New Product Innovation.

Operating loss from continuing operations for the year ended December 31, 2012 was $21.2 million, including $1.8 million in stock-based compensation.